Swedish biotech Cereno Scientific has announced a collaboration with PHA Europe & Global, aimed at integrating the patient perspective more systematically into clinical trial design and execution. Cereno is developing two experimental medications that could expand choices in this space: CS1 for pulmonary arterial hypertension (PAH) and CS014 for pulmonary hypertension associated with lung disease (PH-ILD).
The partnership will focus on incorporating patient insights into study protocols, materials, and communications, with the goal of making clinical trials more relevant and patient-friendly. It will also support broader awareness-raising efforts around pulmonary arterial hypertension and the unmet needs of those living with the condition.
Both organisations emphasised their shared commitment to ensuring that the patient voice is heard and reflected throughout the drug development process.
Read more at this link on the Cereno Scientific press release